Health & TechA personalised melanoma vaccine cut the risk of cancer returning in a large trial
In 1,137 adults, Intismeran plus immunotherapy lowered the chance of death or melanoma returning by 42 percent at two years. It is not approved, and the results are not peer-reviewed yet.
Verified · BBC News


